Amylyx Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
AMLX$30.91+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2023 | 67,707,432 | $7 | $738,177 | $197 | $(304,949) | $433,432 |
| Issuance of common stock upon exercise of stock options | 49,618 | — | 147 | — | — | 147 |
| Issuance of common stock upon vesting of RSUs | 218,537 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 9,924 | — | — | 9,924 |
| Other comprehensive loss | — | — | — | (274) | — | (274) |
| Net loss | — | — | — | — | (118,793) | (118,793) |
| Balance as of March 31, 2024 | 67,975,587 | $7 | $748,248 | $(77) | $(423,742) | $324,436 |
| Issuance of common stock upon exercise of stock options | 59,981 | — | 23 | — | — | 23 |
| Issuance of common stock upon vesting of RSUs | 43,489 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 9,570 | — | — | 9,570 |
| Other comprehensive loss | — | — | — | (20) | — | (20) |
| Net loss | — | — | — | — | (72,700) | (72,700) |
| Balance as of June 30, 2024 | 68,079,057 | $7 | $757,841 | $(97) | $(496,442) | $261,309 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2022 | 66,512,011 | $7 | $694,906 | $(86) | $(354,220) | $340,607 |
| Issuance of common stock upon exercise of stock options | 451,298 | — | 2,777 | — | — | 2,777 |
| Issuance of common stock upon vesting of RSUs | 132,294 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 7,580 | — | — | 7,580 |
| Other comprehensive loss | — | — | — | 111 | — | 111 |
| Net income | — | — | — | — | 1,573 | 1,573 |
| Balance as of March 31, 2023 | 67,095,603 | $7 | $705,263 | $25 | $(352,647) | $352,648 |
| Issuance of common stock upon exercise of stock options | 226,138 | — | 1,687 | — | — | 1,687 |
| Issuance of common stock upon vesting of RSUs | 32,676 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 10,053 | — | — | 10,053 |
| Other comprehensive loss | — | — | — | (97) | — | (97) |
| Net income | — | — | — | — | 22,074 | 22,074 |
| Balance as of June 30, 2023 | $67,354,417 | $7 | $717,003 | $(72) | $(330,573) | $386,365 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.